|
|
Article: Opexa Announces Encouraging Clinical Data on Novel T-Cell Vaccination Therapy for Rheumatoid Arthritis.
- Article from:
- Business Wire
- Article date:
- February 6, 2007
CopyrightCOPYRIGHT 2007 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
THE WOODLANDS, Texas -- Opexa Therapeutics, Inc. (NASDAQ:OPXA), a company involved in the development and commercialization of cell therapies, announced encouraging data from a clinical trial of 15 patients with rheumatoid arthritis (RA). Published in Arthritis & Rheumatism (Vol. 56, No. 2, pp. 453-463), the trial was conducted at the Shanghai Institutes of Biological Sciences, Chinese Academy of Sciences of the People's Republic of China (SIBS), using T-cell vaccination technology exclusively licensed to Opexa. The results demonstrated that T-cell vaccination was well tolerated and, importantly, induced T-cell regulatory immune responses which collectively correlated with ...